Alice E. Till Selected AAPS President-Elect

Article

Till, a PhRMA vice president, will lead AAPS starting in November; Executive Council and Section leadership positions were also announced.

Alice E. Till, PhD, vice president of Science Policy & Technical Affairs at Pharmaceutical Research and Manufacturers of America (PhRMA), has been elected to serve as president-elect of the American Association of Pharmaceutical Scientists (AAPS), a member-based organization of approximately 11,000 located in Arlington, Va. She will begin a three-year term on the AAPS Executive Council (as president-elect, president, and immediate past president) in November, at the 2013 AAPS Annual Meeting and Exposition in San Antonio. The meeting anticipates an attendance of over 8,500 pharmaceutical scientists from around the world.

“On behalf of AAPS, I congratulate Dr. Till on being elected president of the association,” said John Lisack, Jr., CAE, executive director of AAPS. “She has been a tremendous asset to our organization for over 27 years, is a charter member, and AAPS Fellow. A true visionary, Alice will help lead AAPS to new altitudes during her tenure.”

Till stated that during her tenure as president, she will work to ensure AAPS continues to be structurally and functionally prepared to fulfill opportunities, and address the challenges that accompany its position, as well as steadfastly serve the needs of future pharmaceutical scientists.

In addition to the new president-elect, Christopher R. McCurdy, PhD, RPh of the University of Mississippi and Andrew M. Vick, PhD of WIL Research were elected AAPS Members-at-Large. They join Binodh DeSilva, PhD, Russ Weiner, PhD, and Dannette Doolitte, PhD as members of the 2014 AAPS Executive Council.

AAPS also announced leaders for the organization’s nine scientific discipline-based sections:

  • APQ Section Secretary/Treasurer: Eliza Fung, PhD, Bristol-Myers Squibb

  • BIOTEC Section Vice Chair: Meena Subramanyam, PhD, Biogen Idec

  • BIOTEC Section Secretary/Treasurer: Boris Gorovits, PhD, Pfizer, Inc.

  • CPTR Section Vice Chair: Arnab Mukherjee, PhD, Pfizer, Inc.

  • CPTR Section Secretary/Treasurer: John D. Davis, PhD, Genentech Research and Early Development

  • DDDI Section Vice Chair: Robin M. Zavod, PhD, Midwestern University

  • FDD Section Vice Chair: Joseph P. Reo, RPh, PhD, Merck Consumer Care

  • MSE Section Vice Chair: Ruta Y. Waghmare, PhD, EMD Millipore

  • MSE Section Secretary/Treasurer: Claire Scanlan, EMD Millipore

  • PPB Section Vice Chair: Roy Haskell, PhD, Bristol-Myers Squibb

  • PPDM Section Vice Chair: Pankaj B. Desai, PhD, University of Cincinnati

  • PPDM Section Secretary/Treasurer: Shannon Dallas, PhD, Janssen Research and Development, LLC

  • RS Section Secretary/Treasurer: Lynn Gold, PhD, Camargo Pharmaceutical Services

Source: American Association of Pharmaceutical Scientists

Recent Videos
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content